Lung Cancer Ambition Alliance with Giorgio Scagliotti


Despite advancements in oncology treatment and management, lung cancer remains the leading cause of cancer-related death in the USA. With the urgent need to improve survival rates, AstraZeneca, the International Association for the Study of Lung Cancer (IASLC), the Global Lung Cancer Coalition (GLCC) and Guardant Health have teamed up to create the Lung Ambition Alliance.

In this interview we speak with Giorgio Scagliotti (University of Torino, Italy) to find out how the Lung Ambition Alliance is looking to one day eliminate lung cancer as a cause of death and double the 5-year survival rate for the disease by 2025.